FEDERAL HEALTH COUNSEL, LLC

Lobbying for AMGEN, INC. · Pharmaceutical Company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · posted Jun 2, 2026

Lobbying activity 1

Medicare/Medicaid

Issues related to the implementation of the Medicare Drug Negotiations and the calculation of the Medicaid Rebate and Best Price. issues relating to MFN pricing and other price controls in drugs.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.